arrow
L

Lazar Popović

University of Novi Sad
H指数:15
被引数:944

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study

早期/转移性三阴性乳腺癌中PD-L1阳性的真实世界患病率:全球回顾性观察性VANESSA研究的主要结果及病理学见解

2026-02-220
OAAI
Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results

根据PD-L1状态,在真实世界环境中接受治疗的>2000例早期或转移性三阴性乳腺癌患者的治疗模式与临床结局:VANESSA研究结果

2026-02-050
OAAI
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset

预后免疫疗法评分(PIS)在经帕博利珠单抗治疗的晚期尿路上皮癌患者中的真实世界数据及ARON-2数据集验证

2025-09-060
PRE
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
2025-03-140
OAAI
Real-world treatment patterns in patients with human epidermal growth factor receptor 2 (HER2) - positive early breast cancer in Serbia and Montenegro - HEReNA

塞尔维亚和黑山地区人表皮生长因子受体2(HER2)阳性早期乳腺癌患者的真实世界治疗模式——HEReNA

BREAST
IF7.9
2025-02-010
OAAI
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
2024-10-010
OAAI
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

放疗加pembrolizumab治疗晚期尿路上皮癌: 来自ARON-2真实世界研究的结果

2024-08-270
OAAI
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
2021-12-0622
OAAI
Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth
2020-11-199
OAAI
A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries
2020-08-0128
OAAI
Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results
2019-02-151
PRE